SCHOTT Pharma KGaA (1SXP) Panoramica del titolo
SCHOTT Pharma AG & Co. KGaA sviluppa, produce e vende soluzioni di contenimento dei farmaci e sistemi di somministrazione per farmaci iniettabili per le industrie farmaceutiche, biotecnologiche e delle scienze biologiche di tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 2/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per 1SXP dai nostri controlli di rischio.
1SXP Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di SCHOTT Pharma AG & Co. KGaA
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €17.32 |
| Massimo di 52 settimane | €30.25 |
| Minimo di 52 settimane | €12.62 |
| Beta | 0.94 |
| Variazione di 1 mese | 10.32% |
| Variazione a 3 mesi | 27.73% |
| Variazione di 1 anno | -42.17% |
| Variazione a 3 anni | n/a |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -44.66% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 02
1SXP: Confirmed 2026 Guidance And Earnings Quality Will Support Future Upside
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly higher to about €19.43 from roughly €19.14, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News SCHOTT Pharma KGaA has confirmed its earnings guidance for the 2026 financial year.Articolo di analisi • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...
Aggiornamento della narrazione • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.Recent updates
Aggiornamento della narrazione • Jun 02
1SXP: Confirmed 2026 Guidance And Earnings Quality Will Support Future Upside
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly higher to about €19.43 from roughly €19.14, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News SCHOTT Pharma KGaA has confirmed its earnings guidance for the 2026 financial year.Articolo di analisi • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...Aggiornamento della narrazione • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.Aggiornamento della narrazione • Apr 29
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Aggiornamento della narrazione • Apr 14
1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).Aggiornamento della narrazione • Mar 31
1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).Aggiornamento della narrazione • Mar 17
1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.Aggiornamento della narrazione • Mar 03
1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).Aggiornamento della narrazione • Feb 17
1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).Articolo di analisi • Feb 14
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) defied analyst predictions to release its first-quarter results, which were...
Aggiornamento della narrazione • Feb 02
1SXP: Fair Outlook Will Balance Dividend Payout With Leadership Transition
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €14.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that they see as balancing out overall. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, payable on February 6, 2026, with an ex date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Articolo di analisi • Feb 02
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 18x, you may consider...Aggiornamento della narrazione • Jan 19
1SXP: Dividend Initiation Will Support Confidence In Revised Long Term Outlook
Analysts have reduced their price target for SCHOTT Pharma KGaA from €36.00 to €26.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which point to a more conservative outlook on the shares' fair value. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, an ex dividend date on February 4, 2026, and a record date on February 5, 2026 (Key Developments).Aggiornamento della narrazione • Jan 05
1SXP: Leadership Transition And Dividend Policy Will Support Future Profitability
Analysts have trimmed their fair value estimate for SCHOTT Pharma KGaA from €28.28 to €22.97, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple as key drivers of the change. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, ex-date on February 4, 2026, and record date on February 5, 2026 (Key Developments).Aggiornamento della narrazione • Dec 20
1SXP Outlook Will Balance Lower Expectations With Dividend And Leadership Transition
Analysts have reduced their price target on SCHOTT Pharma KGaA from €22.00 to €14.00, reflecting tempered expectations for revenue growth, profit margins, and future valuation multiples in an environment characterized by higher discount rates. What's in the News SCHOTT Pharma AG & Co. KGaA declared an annual dividend of EUR 0.18 per share, payable on February 6, 2026, with an ex-dividend date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).Articolo di analisi • Dec 15
SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) has announced that it will be increasing its periodic dividend on the 6th of...Aggiornamento della narrazione • Dec 06
1SXP: Leadership Transition Will Support Future Profitability And Operational Discipline
Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.Articolo di analisi • Nov 24
A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights SCHOTT Pharma KGaA's estimated fair value is €21.30 based on 2 Stage Free Cash Flow to Equity With €18.44...Aggiornamento della narrazione • Nov 22
1SXP: Leadership Transition Will Drive Renewed Operational Focus And Profitability
Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models. What's in the News Christian Mias appointed as CEO of SCHOTT Pharma KGaA.Articolo di analisi • Nov 02
Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Sep 19
Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Articolo di analisi • Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its quarterly result to the...Articolo di analisi • Jul 19
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Jun 13
Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) came out with its second-quarter results last week, and we wanted to see how...Articolo di analisi • Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Key Insights SCHOTT Pharma KGaA's estimated fair value is €39.60 based on 2 Stage Free Cash Flow to Equity SCHOTT...Articolo di analisi • Mar 22
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Feb 12
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Articolo di analisi • Jan 13
Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €49.59 based on 2 Stage Free Cash Flow to Equity SCHOTT...
Nuova narrazione • Dec 16
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.Articolo di analisi • Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
SCHOTT Pharma AG & Co. KGaA's ( ETR:1SXP ) price-to-earnings (or "P/E") ratio of 31.5x might make it look like a strong...Articolo di analisi • Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) investors will be delighted, with the company turning in some strong numbers...Articolo di analisi • Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €47.81 based on 2 Stage Free Cash Flow to Equity Current...Articolo di analisi • Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
It's been a pretty great week for SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) shareholders, with its shares surging 11% to...Articolo di analisi • Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights The projected fair value for SCHOTT Pharma KGaA is €34.80 based on 2 Stage Free Cash Flow to Equity SCHOTT...Rendimenti per gli azionisti
| 1SXP | DE Life Sciences | DE Mercato | |
|---|---|---|---|
| 7D | -2.0% | -3.0% | -2.6% |
| 1Y | -42.2% | -6.7% | -1.4% |
Ritorno vs Industria: 1SXP ha avuto una performance inferiore rispetto al German Life Sciences che ha registrato un rendimento -6.7 % nell'ultimo anno.
Rendimento vs Mercato: 1SXP ha avuto una performance inferiore al mercato German che ha registrato un rendimento -1.4 % nell'ultimo anno.
Volatilità dei prezzi
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
Prezzo delle azioni stabile: 1SXP non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di 1SXP è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1884 | 4,839 | Christian Mias | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA sviluppa, produce e vende soluzioni di contenimento e sistemi di somministrazione di farmaci iniettabili per le industrie farmaceutiche, biotecnologiche e delle scienze biologiche di tutto il mondo. L'azienda offre siringhe in vetro o polimero, fiale in vetro, cartucce e fiale preriempite. I suoi prodotti includono syriQ, una siringa in vetro per vaccini; syriQ BioPure, una siringa in vetro per farmaci biologici; syriQ BioPure senza silicone, una siringa in vetro prefillabile e senza silicone per farmaci biologici; SCHOTT TOPPAC, una siringa in polimero; SCHOTT TOPPAC cosmetic, una siringa in polimero per trattamenti estetici; SCHOTT TOPPAC freeze, una siringa in polimero per applicazioni di freddo profondo; SCHOTT TOPPAC sensitive, una siringa in polimero per farmaci sensibili; SCHOTT TOPPAC infuse, una siringa in polimero per la terapia infusionale; e SCHOTT TOPPAC unique, un contenitore in polimero.
SCHOTT Pharma AG & Co. KGaA Riepilogo dei fondamenti
| 1SXP statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €2.61b |
| Utili (TTM) | €142.82m |
| Ricavi(TTM) | €991.22m |
18.3x
Rapporto P/E2.6x
Rapporto P/S1SXP è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 1SXP Conto economico (TTM) | |
|---|---|
| Ricavi | €991.22m |
| Costo del fatturato | €664.75m |
| Profitto lordo | €326.47m |
| Altre spese | €183.65m |
| Utili | €142.82m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 12, 2026
| Utile per azione (EPS) | 0.95 |
| Margine lordo | 32.94% |
| Margine di profitto netto | 14.41% |
| Rapporto debito/patrimonio netto | 23.7% |
Come si è comportato 1SXP nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.0%
Rendimento attuale del dividendo19%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/11 00:42 |
| Prezzo dell'azione a fine giornata | 2026/06/11 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
SCHOTT Pharma AG & Co. KGaA è coperta da 23 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |